Neuromyelitis Optica Spectrum Disorder Developing after COVID-19 Vaccination Managed with Long-Term Eculizumab Treatment: A Case Report
Owing to the risk of severe disease, such as NMOSD, in patients who initially present with nonspecific neurological symptoms following vaccination, careful examination and monitoring are essential to ensure treatment can be started as soon as possible. Once diagnosed, eculizumab is an effective treatment for patients with AQP4-positive NMOSD following vaccination.
Authors
- Naoki Morishita (ORCID: https://orcid.org/0000-0002-6421-5858)
- Youji Suzuki
- Akihito Koseki
- Kyoko Oka (ORCID: https://orcid.org/0000-0002-1648-1596)
- Naoki Sakai (ORCID: https://orcid.org/0000-0002-3754-7478)
- Keigo Nakamura (ORCID: https://orcid.org/0000-0003-2570-9529)
- Shugo Uchida
Institutions
- Shizuoka University of Welfare (JP)
Publication Details
- Journal
- Case Reports in Neurology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1159/000549443
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Alexion Pharmaceuticals